Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWTG.L Regulatory News (WTG)

  • There is currently no data for WTG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close trading update

31 Jan 2019 07:00

RNS Number : 6093O
Watchstone Group PLC
31 January 2019
 

Watchstone Group plc

 

("Watchstone" or the "Group")

 

Pre-close trading update

 

 

Watchstone Group plc (LON:WTG) today issues a pre-close trading update ahead of its results for the year ended 31 December 2018.

 

Revenue (unaudited):

year ended 31 December

2018

 

2017

 

Healthcare services

£30.0m (C$51.8m)

£30.5m (C$51.1m)

ingenie

£7.7m

£14.4m

Total

£37.7m

£44.9m

 

Cash and term deposits on 31 December 2018 totalled £50.1m (£58.4m as at 30 June 2018) excluding the £50.2m in escrow pending resolution or determination of the claim issued by Slater & Gordon (UK) 1 Limited ("Slater & Gordon Claim").

 

Healthcare services:

 

Healthcare services consists of our Canadian ptHealth clinics business and InnoCare, our clinic software, referral network and managed services business. In the year, the Healthcare services division grew revenues in local currency despite the sale and conversion to a managed service offering of one of its underperforming clinics. However, adverse movements in the Canadian Dollar relative to Sterling has resulted in lower revenues being recorded overall in Sterling.

 

During the second half of 2018, ptHealth was appointed as the Canadian Arthritis Society's national physiotherapy provider and also became the first physiotherapy provider officially certified as a Great Place to Work® by the Great Place to Work® Institute Canada.

 

As anticipated, a significant proportion (39%, C$4.23m (approximately £2.5m)) of the preference shares in the business have been redeemed in the year. Profitability is expected to be broadly flat relative to 2017 however a significant restructuring of the clinic business has been completed in the year which more closely aligns costs to revenues and should create more optimal conditions for profitable growth.

 

ingenie:

 

As previously described, challenging trading conditions have continued to further impact retail volumes. A number of initiatives have been undertaken to address these issues including the recent broadening of underwriting partnerships and this has seen positive, albeit early, trends. Further structural changes to the business continue which are anticipated to revive the retail competitiveness of the offering during H1 2019.

 

The ANWB programme is performing well and underlines the credibility and relevance of ingenie's business to business offering. ingenie's B2B pipeline is strong with a variety of opportunities being pursued with vigour.

 

Central costs and overall results:

Central costs were rationalised at the end of 2017 and this is reflected in materially lower expenditure during 2018.

 

Legacy matters:

The Slater & Gordon Claim is ongoing and the disclosure process commenced in December 2018. Our position remains that Slater & Gordon's allegations of deceit and the associated breach of warranty claim are wholly without merit and should never have been advanced. During the year, significant costs have been incurred in defence of this claim and we continue to bolster the provision for legal costs in anticipation of a trial commencing in October 2019. In parallel, we continue to pursue any deferred consideration due from Slater & Gordon in respect of the disposal of the PSD.

 

The SFO investigation continues and we are cooperating fully. It remains the only regulatory inquiry to which the Group is subject.

 

2019 outlook:

 

2019 will be an important year for the Group both in terms of growing its operating businesses and dealing with the Group's legacy issues as efficiently as possible.

 

 

For further information:

 

Watchstone Group plc

Tel: 03333 448048

 

Peel Hunt LLP, Nominated Adviser and Broker

 

Tel: 020 7418 8900

Dan Webster

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLIFIILVILVIA
Date   Source Headline
30th Nov 20127:00 amRNSQuindell awarded TM Forum's Certification Mark
16th Nov 20127:00 amRNSRecognition in Celent Report
15th Nov 20127:00 amRNSQuindell Earns High Ranking Among Industry Peers
14th Nov 20127:00 amRNSEquity placing for organic growth
12th Nov 20127:00 amRNSAward Success at Quindell
7th Nov 20127:00 amRNSProperty Claims Contract Win
6th Nov 201212:46 pmRNSNotification of Major Interest in Shares
5th Nov 20127:00 amRNSQuindell & NTT Data partner
2nd Nov 20127:01 amRNSRobert Thomson Appointment Confirmed
2nd Nov 20127:00 amRNSPlacing to raise £26.5 million
1st Nov 20127:00 amRNSIssue of Warrants
29th Oct 20122:35 pmRNSTrading Update
25th Oct 20127:00 amRNSQuindell recognised in Celent Claims report
15th Oct 20127:01 amRNSQ3 Trading Statement & Advisory Board Appointment
15th Oct 20127:00 amRNSAgreement with Pinto Potts Solicitors
10th Oct 20127:00 amRNSAcquisition of Metaskil
26th Sep 20127:00 amRNSAcquisition and Increase in Director Shareholding
18th Sep 20127:00 amRNSMajor Contract Win and Acquisition
4th Sep 20127:01 amRNSInterim Results
4th Sep 20127:00 amRNSExercise of Warrants
15th Aug 20127:00 amRNSCompletion of Acquisition and Strategy Update
13th Aug 20127:10 amRNSNotice of Results
13th Aug 20127:00 amRNSNotice of Analyst and Investor Teach-in
9th Jul 20127:00 amRNSPre Close Trading Statement
4th Jul 20127:00 amRNSUpdate on Software & Consulting division
29th Jun 201211:00 amRNSResult of AGM
28th Jun 20127:00 amRNSAnnual Report and Accounts
27th Jun 20127:00 amRNSFurther Agreement and Update on Silverbeck Rymer
15th Jun 20127:00 amRNSCommercial Agreement and Acquisition Terms
14th Jun 20127:00 amRNSRecommended Mandatory Cash Offer for Ai Claims
30th May 20127:00 amRNSDirector/PDMR Shareholding
24th May 20127:00 amRNSQuindell extends its technology capability
16th May 201211:28 amRNSForm 8 (DD) - [Quindell Portfolio]
15th May 20125:40 pmRNSOffer Update and Unconditional in all respects
15th May 201211:37 amRNSForm 8 (DD) - [Quindell Portfolio]
14th May 201210:12 amRNSForm 8 (DD) - [Quindell Portfolio]
14th May 20127:00 amRNSAppointment and acquisition
11th May 20121:44 pmRNSForm 8.3 - QUINDELL PORTFOLIO
11th May 201212:57 pmRNSForm 8.3 - Quindell Portfolio plc Replacement
11th May 201212:13 pmRNSForm 8.3 - Quindell Portfolio plc
11th May 201210:59 amRNSForm 8 (DD) - Quindell Portfolio
10th May 20123:07 pmRNSForm 8.3 - QUINDELL PORTFOLIO PLC
10th May 201212:05 pmRNSForm 8 (DD) - Quindell Portfolio PLC
9th May 201211:49 amRNSForm 8.3 - QUINDELL PORTFOLIO PLC
9th May 201211:44 amRNSForm 8 (DD) -Quindell Portfolio
9th May 20127:00 amRNS£120 Million Contract Win
8th May 201212:15 pmRNSForm 8 (DD) - Quindell Portfolio plc
4th May 201210:38 amRNSForm 8 (DD) - Quindell Portfolio
3rd May 201210:20 amRNSForm 8 (DD) - Quindell Portfolio PLC
2nd May 201210:37 amRNSForm 8 (DD) - Quindell Portfolio

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.